Here are the 10-Q quarterly reports from NeoGenomics, Inc. (NEO) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow NEO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NEO filings page.
NeoGenomics, Inc. (NEO) reported third-quarter revenue of $209.3 million, compared with $187.8 million a year earlier, while net loss narrowed to $7.5 million from $27.1 million. For the nine months ended September 30, 2026, revenue was $597.6 million and net loss was $22.4 million, versus $537.2 million and $98.1 million, respectively, in 2025. Operating cash flow was $2.9 million for the nine-month period, compared with $3.9 million.
On June 22, 2026, NeoGenomics issued $316.3 million aggregate principal amount of 0.75% convertible senior notes due 2032, generating approximately $305.7 million in net proceeds. It used offering proceeds to repurchase a portion of its 2028 notes for $262.9 million and repurchased 2,383,222 common shares for $25.0 million. On July 20, 2026, NeoGenomics paid $10.0 million in a civil settlement with the U.S. Department of Justice on behalf of the HHS Office of Inspector General concerning consulting services under its Laboratory Collaboration Initiative. The settlement resolved the investigation, required no corporate integrity agreement or additional ongoing compliance obligations, and was not an admission of liability.
NeoGenomics, Inc. reported net revenue of $201,656 (dollars in thousands) for the quarter ended June 30, 2026, up from $181,330 a year earlier, with gross profit increasing to $91,878. Operating expenses declined, partly due to the absence of prior-year impairment charges, and loss from operations narrowed to $9,771 (all in thousands).
After interest income and an $11,181 gain on extinguishment of debt, NeoGenomics generated quarterly net income of $2,238 versus a prior-year net loss of $45,092 (dollars in thousands); for the first six months, it recorded a net loss of $14,868 on revenue of $388,328. Cash and cash equivalents were $145,539, and total stockholders’ equity $785,732 (dollars in thousands) as of June 30, 2026.
During the quarter, the company issued $316.3 million of 0.75% Convertible Senior Notes due 2032, using proceeds to repurchase a portion of its 2028 notes for $262.9 million in cash, enter $28.7 million of equity-classified capped call transactions, and repurchase 2,383,222 shares for $25.0 million. A subsequent civil settlement with the U.S. Department of Justice requires payment of $10.0 million and reduced a previously recorded reserve by about $1.2 million, producing a benefit in general and administrative expense.
NeoGenomics, Inc. reported Q3 2025 results with net revenue of $187.8 million, up from $167.8 million a year ago, as testing volumes and payer mix lifted sales. Gross profit was $80.4 million. The company posted a net loss of $27.1 million (basic and diluted loss per share of $0.21), reflecting higher operating expenses and impairment charges.
Operating loss was $27.0 million, including a $7.1 million impairment tied to a business classified as held for sale. Year to date, net revenue reached $537.2 million and net loss was $98.1 million. Cash and cash equivalents were $164.1 million as of September 30, 2025, after repaying $201.3 million of 2025 convertible notes and $1.3 million of interest in May. Operating cash flow was $3.9 million for the first nine months.
The company closed the Pathline acquisition for $8.5 million; Pathline contributed $4.6 million of revenue in Q3 and recorded a net loss of $2.2 million. Assets held for sale related to Trapelo totaled $2.1 million, and total impairment for the disposal group was $15.3 million year to date. As of October 24, 2025, shares outstanding were 129,387,801.